|  | Human LILRB2/CD85d/ILT4 Protein (LTP10495) | 
    
    |  | LTP10495 | 
    
    |  | 100ug | 
    
    |  | 
    $305 In stock | 
 |  | The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC). LILRB2 is a receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. | 
|  | Recombinant Human LILRB2/CD85d/ILT4 Protein is expressed from Expi293 with hFc tag at the C-terminal. It contains Gln22-His458. | 
    
    |  | LILRB2/CD85d/ILT4 | 
    
    |  | Human | 
    
    |  | Q8N423-1 | 
    
    
    |  | Gln22-His458 | 
    
    |  | The protein has a predicted MW of 74.1 kDa. Due to glycosylation, the protein migrates to 80-110 kDa based on the Tris-Bis PAGE result. | 
    
    |  | Immobilized Human LILRB2, hFc Tag at 1ug/ml (100ul/well) on the plate. Dose response curve for Biotinylated Anti-LILRB2 Antibody, hFc Tag with the EC50 of 16.5ng/ml determined by ELISA (QC Test). The affinity constant of 9.20nM as determined in SPR assay (Biacore T200). See testing image for detail. | 
    
    |  | C-hFc | 
    
    |  | Expi293 | 
    
    
    
    |  | > 95% as determined by Tris-Bis  PAGE; > 95% as determined by SEC-HPLC | 
    
    |  | Less than 1EU per ug by the LAL method. | 
    
    |  | Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as a protectant before lyophilization. | 
    
    |  | Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. | 
    
    |  | Shipped at ambient temperature. | 
    
    |  | Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. | 
    
    |  |  |